Abstract
Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Recent Patents on Biotechnology
Title:Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Volume: 10 Issue: 2
Author(s): Nabila Sorathia and Medha S. Rajadhyaksha
Affiliation:
Keywords: Anti-bacterial molecules, Caenorhabditis elegans, drug screening, human gut pathogens, innate immunity model organism.
Abstract: Novel clinical strategies need to be evolved, as pathogens, especially the ones that infect the human, develop resistance. To do so, host pathogen biology needs to be clearly understood and this can be done using a nematode worm, Caenorhabditis elegans, which harbours the same virulent microbes. Over several decades, the worm has been used to study host-microbe interaction with reference to immune response of the worm, antimicrobial molecules secreted, cell death in the worm body, quorum sensing network of the bacteria and fast or slow worm death. This mini review gives a bird’s eye view of the directions that have been taken in these areas to date. Currently, the worm has been proposed to be an ideal model for high throughput screening of natural and synthetic drugs against a variety of bacteria. Experimental systems that allow this screening have been patented. Caenorhabditis elegans, thus, is one of the very effective models for studying pathogens that infect human.
Export Options
About this article
Cite this article as:
Sorathia Nabila and Rajadhyaksha S. Medha, Caenorhabditis elegans: A Model for Studying Human Pathogen Biology, Recent Patents on Biotechnology 2016; 10 (2) . https://dx.doi.org/10.2174/1872208310666160727151853
DOI https://dx.doi.org/10.2174/1872208310666160727151853 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Corynebacterium Striatum</i>, an Emerging Nosocomial Pathogen: Case Reports
Infectious Disorders - Drug Targets Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Assay of Daptomycin Injection: Development and Validation of an Environment-friendly CZE Method
Current Pharmaceutical Analysis Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Preface
Recent Patents on Anti-Infective Drug Discovery The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020
Current Pharmaceutical Biotechnology Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Current Vascular Pharmacology Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry Riboswitches as Potential Targets for the Development of Anti-Biofilm Drugs
Current Topics in Medicinal Chemistry Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Nanomedical Strategies for Targeting Skin Microbiomes
Current Drug Metabolism Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry Antimicrobial Peptides as Anti-biofilm Agents in Medical Implants
Current Topics in Medicinal Chemistry β-Lactams in the New Millennium. Part-II: Cephems, Oxacephems, Penams and Sulbactam
Mini-Reviews in Medicinal Chemistry